Lupin draws an aggressive plan for US
The company plans to launch 20-25 products each year in the US.
New Delhi, May 12, 2013: Lupin, the fifth largest generics player in the US, plans to launch 20-25 new products every year for the next couple of years in the US market. The company is aiming to further consolidate its business in the US and at the same time, is looking to acquire brands to be able to sustain growth levels of up to 25 per cent in the current fiscal.
The company filed for 21 ANDAs and received 14 approvals from the USFDA in 2012-13. In fact, its cumulative ANDA filings with the USFDA as of March 2013 stood at 176 with the company having received 78 approvals to date.
The company has a plan to acquire brand in the paediatrics, cardiovascular and dermatology therapeutic areas. The company already has 12 oral contraceptive product approvals in the US.
Lupin is the market leader in 24 products out of the 46 products marketed in the US generics market, as per IMS Health March, 2013 sales data.